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Summary
 
Antagonist peptides inhibit T cell responses by an unknown mechanism. By coexpressing two
independent T cell receptors (TCRs) on a single T cell hybridoma, we addressed the question
of whether antagonist ligands induce a dominant-negative signal that inhibits the function of a
second, independent TCR. The two receptors, V
 
a
 
2V
 
b
 
5 and V
 
a
 
2V
 
b
 
10, restricted by H-2K
 
b
 
and specific for the octameric peptides SIINFEKL and SSIEFARL, respectively, were coex-
pressed on the same cell. Agonist stimulation demonstrated that the two receptors behaved in-
dependently with regard to antigen-induced TCR downregulation and intracellular biochemi-
cal signaling. The exposure of one TCR (V
 
a
 
2V
 
b
 
5) to antagonist peptides could not inhibit a
second independent TCR (V
 
a
 
2V
 
b
 
10) from responding to its antigen. Thus, our data clearly
demonstrate that these antagonist ligands do not generate a dominant-negative signal which af-
fects the responsiveness of the entire cell. In addition, a kinetic analysis showed that even 12 h
after engagement with their cognate antigen and 10 h after reaching a steady-state of TCR in-
ternalization, T cells were fully inhibited by the addition of antagonist peptides. The window
of susceptibility to antagonist ligands correlated exactly with the time required for the respond-
ing T cells to commit to interleukin 2 production. The data support a model where antagonist
ligands can competitively inhibit antigenic peptides from productively engaging the TCR.
This competitive inhibition is effective during the entire commitment period, where sustained
TCR engagement is essential for full T cell activation.
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T
 
cell activation depends on the specific recognition of
peptides presented in the binding groove of MHC
molecules (1, 2). The binding of the peptide/MHC ligand
to the TCR leads to the tyrosine phosphorylation of TCR-
associated proteins, recruitment of kinases and adapters, and
activation of intracellular signaling pathways (3–6). Inter-
estingly, T cells can differentially respond to subtle changes
in either the MHC or peptide ligand. Substitutions in
TCR contact residues can give rise to antagonist ligands
that do not elicit any measurable T cell effector functions,
but are able to diminish or even abrogate the response to
the nominal antigen when both the agonist and antagonist
are simultaneously displayed on APCs (7–11).
Various models have been proposed to explain the
mechanistic basis for the differential response to antagonist
ligands by the same TCR and its translation into altered
signaling and T cell activation (12–16). First, a quantitative
model has been put forward which proposes that TCR an-
tagonism is due to the fact that antagonist ligands interact
nonproductively with the TCR, and competitively inhibit
antigenic ligands from productively engaging the TCR.
This competition might disturb the formation of necessary
signaling oligomers (7, 12, 17–19). This model is supported
by studies showing that several antagonist ligands fail to in-
duce TCR-dependent signaling events such as the genera-
tion of sustained Ca
 
2
 
1
 
 flux and turnover of the inositol
phosphates (7, 9, 17, 20–22) as well as exhibit lower affini-
ties and faster off-rate kinetics for the TCR than antigenic
ligands (23–25).
In contrast, various qualitative models have been pro-
posed where antagonist ligands induce a TCR-mediated
differential (8, 9, 16, 21, 26–28) or even negative signal
(13, 14, 29, 30). One model attributes the induction of a
negative signal to an inappropriate conformational change
induced by antagonist ligands (14, 31). In contrast, another
model proposes that quantitative differences in TCR/
ligand binding translate into a negative intracellular signal
(29). Studies of positive selection of immature thymocytes 
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by antagonist ligands in fetal thymic organ culture have
shown that these ligands are in fact capable of delivering a
signal through the TCR (32–34). Moreover, several groups
have demonstrated that altered peptide ligands, with partial
agonist or with even pure antagonist properties, were able
to initiate some but not all of the early biochemical events
associated with TCR signaling (26–28). Although these ex-
periments provided evidence for the induction of differen-
tial signaling events induced by partial agonist and antago-
nist ligands, they were not able to distinguish whether the
observed inhibitory effect was due to an induced negative
signal or to incomplete activation based on the faster TCR
dissociation from the antagonist/MHC complex (24, 25).
In the present study, we have addressed the mechanism
of antagonism induced by antagonist ligands using T cell
hybridomas coexpressing two independent TCRs. If antag-
onist ligands induced signals with negative regulatory char-
acteristics, then stimulation through one receptor should be
inhibitable by antagonizing the other. Our data clearly
demonstrate that the antagonist ligands we examined do
not generate such an intracellular dominant-negative signal
which inhibits the stimulation of a second independent
TCR. The two TCRs, expressed on the same cell, be-
haved independently with regard to antigen-induced TCR
internalization as well as intracellular biochemical signaling.
Interestingly, the T cell hybridoma could be inhibited by
antagonist peptides far beyond the time point of maximal
antigen-induced TCR internalization. The fact that the
window of sensitivity to antagonist peptides correlated ex-
actly with the time required for the cells to commit to acti-
vation supports a competitive model to explain TCR an-
tagonism.
 
Materials and Methods
 
DNA Constructs.
 
The OVA-TCR-1 (OT-I) is comprised of
rearranged TCR 
 
a
 
 (V
 
a
 
2-J
 
a
 
26) and TCR 
 
b
 
 (V
 
b
 
5-D
 
b
 
2-J
 
b
 
2.6)
chains and is derived from the K
 
b
 
-restricted, OVA
 
257-264
 
-specific
CTL clone, 149.42 (35). The cDNA encoding the TCR 
 
a
 
 chain
was cloned into the G418 resistant retroviral vector, LXSN (36–
38). Similarly, the OT-I TCR 
 
b
 
 chain was cloned into the puro-
mycin resistant retroviral vector, LXSP (39). The TCR 
 
b
 
 chain
(V
 
b
 
10-D
 
b
 
2-J
 
b
 
2.5), when paired with the OT-I V
 
a
 
2 chain, con-
fers specificity for the Herpes simplex viral peptide, SSIEFARL
(40). The V
 
b
 
10 cDNA was cloned into LXSP as well. The
cDNAs encoding CD8
 
a
 
 and CD8
 
b
 
 were kindly provided by P.
Cosson (University of Geneva, Geneva, Switzerland). The CD8
 
a
 
cDNA was cloned into the retroviral vector LXSHD, which ex-
presses a histidinol resistance gene, while the CD8
 
b
 
 cDNA was
similarly cloned into the retroviral vector LXSH, containing a
hygromycin resistance gene. LXSHD and LXSH were provided
by A. Kazlauskas (Harvard Medical School, Boston, MA).
 
Cells.
 
The TCR-
 
a
 
2
 
/
 
b
 
2
 
 T hybridoma, 58, has been de-
scribed previously (41). The 58CD8
 
a
 
/
 
b
 
 cells were generated by
sequentially infecting the original cell line 58 with supernatants
containing viruses encoding CD8
 
a
 
 and CD8
 
b
 
. Subsequently, the
TCR 
 
a
 
 and 
 
b
 
 chains were transfected by retroviral infection of
58CD8
 
a
 
/
 
b
 
 to obtain cell lines expressing a single TCR
(V
 
a
 
2V
 
b
 
5 or V
 
a
 
2V
 
b
 
10). Similarly, retroviral infection and cell
sorting was used to generate a cell line coexpressing two TCRs
 
(V
 
a
 
2V
 
b
 
5 and V
 
a
 
2V
 
b
 
10). The P1.32K
 
b
 
 cell line, directed from
the cell line P815 by transfection of a DNA construct encoding
the MHC class I molecule K
 
b
 
 (42), was used for peptide presenta-
tion. All cells were grown in IMDM supplemented with 1.5%
heat inactivated FCS, 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin,
100 
 
m
 
g/ml streptomycin, and 50 
 
m
 
M 
 
b
 
-mercaptoethanol. The
indicator cell line HT-2 (43) was grown in IMDM containing
5% FCS with the addition of 250 U/ml recombinant IL-2. The
ecotropic packaging cell line Bosc23 was purchased from Ameri-
can Type Culture Collection and grown in IMDM containing
10% FCS.
 
Transfection and Infection.
 
Bosc23 packaging cell line was
transfected as described previously (44). The supernatant contain-
ing retroviral particles was used to infect the 58 T cell hybridoma.
Briefly, 5 
 
3
 
 10
 
5
 
 58 cells were resuspended in 100 
 
m
 
l IMDM, and
1 ml retroviral supernatant containing 40 
 
m
 
g DEAE-dextran was
added. After 6–12 h, 5 ml of fresh IMDM and the appropriate se-
lective drug was added (1 mg/ml G418 [GIBCO BRL], 3 
 
m
 
g/ml
puromycin [Sigma Chemie], 2 mM histidinol [Sigma Chemie],
or 0.5 mg/ml hygromycin [Calbiochem]). The surviving cells
were analyzed after 5–7 d and sorted for surface expression by
FACS
 
®
 
. In all experiments at least two independently generated
T cell hybridoma lines were compared, and similar results were
obtained. Transfected cells were always maintained in medium
containing the selective drugs.
 
Peptides.
 
The peptides were synthesized at the Basel Institute
for Immunology using FastMoc
 
TM
 
 chemistry on 430A peptide
synthesizer (Applied Biosystems). The amino acid sequences were
the following: SIINFEKL (V
 
a
 
2V
 
b
 
5-specific antigen), EIINFEKL
(V
 
a
 
2V
 
b
 
5-specific antagonist E1), SIINFEPL (V
 
a
 
2V
 
b
 
5-specific
antagonist P7), SIIKFEKL (the control peptide K4), and SSIEFARL
(V
 
a
 
2V
 
b
 
10-specific antigen).
 
Antibodies.
 
The anti-V
 
b
 
5 mAb, MR9-4 (44), anti-CD3
 
e
 
mAb, 2C11 (45), and anti-
 
z
 
 mAb, H146-968 (46), were purified
from culture supernatants using protein G (Pharmacia). The anti-
V
 
a
 
2.1–specific mAb, B20.1 (47), the anti-V
 
b
 
10 mAb, B21.5 (48),
and the anti-K
 
b
 
 mAb, AF6-88.5 (49), were purchased from Phar-
Mingen. The anti-phosphotyrosine mAb, 4G10, was purchased
from Upstate Biotechnology. To detect bound anti-
 
z
 
 antibodies in
Western blots, we used goat anti–rabbit antibodies labeled with
horseradish peroxidase (HRPO)
 
1
 
 from Southern Biotechnology
Associates. The blocking anti-K
 
b
 
 mAb, provided by J. Bluestone,
was purified from culture supernatants using protein A (50).
 
Quantitation of TCR Surface Expression.
 
To calculate the rela-
tive amount of the two TCRs (V
 
a
 
2V
 
b
 
5 and V
 
a
 
2V
 
b
 
10) coex-
pressed on the same hybridoma cell, the expression of each TCR
 
b
 
 chain (measured by staining with the appropriate anti-V
 
b
 
mAb) was normalized to the total amount of TCR expressed on
the surface (measured by staining with an anti-V
 
a
 
2 mAb). The
ratio of V
 
b
 
5/V
 
a
 
2 or V
 
b
 
10/V
 
a
 
2 staining on cells expressing a
single TCR was taken as 100%. On the surface of the hybridomas
expressing two TCRs, V
 
a
 
2V
 
b
 
5 and V
 
a
 
2V
 
b
 
10 heterodimers ac-
counted for 60 and 40% of the surface TCRs, respectively.
 
Stimulation Assays.
 
90 
 
m
 
l containing 5 
 
3
 
 10
 
4
 
 P1.32K
 
b
 
 cells
was plated in flat-bottomed 96-well plates and incubated with
10 
 
m
 
l peptide for 4 h at 37
 
8
 
C. 8 
 
3
 
 10
 
4
 
 T hybridoma cells in 100 
 
m
 
l
medium were subsequently added. After a further 25 h of incuba-
tion at 37
 
8
 
C, the supernatant was harvested and assayed for IL-2.
Antagonism Assays. P1.32Kb cells were first loaded for 4 h at
378C with the indicated amount of agonist peptide and unbound
1Abbreviation used in this paper: HRPO, horseradish peroxidase.255 Stotz et al.
peptide was removed by washing. Peptide loaded cells (5 3 104/
90 ml) were plated in flat-bottom 96-well plates. 10 ml of antago-
nist peptides, or 10 ml of control peptide or medium alone was
added and the cultures were incubated at 378C for 1 h. 8 3 106 T
hybridoma cells in 100 ml were then added and incubated for 25–
27 h at 378C. The supernatant was harvested and analyzed for the
presence of IL-2.
IL-2 Assay. IL-2 content was determined by incubating 2 3
103 HT-2 cells per well in round-bottom 96-well plates with se-
rial dilutions of culture supernatant for 24 h. Alamar blue sub-
strate (Alamar Biosciences) was then added and IL-2 titer was de-
termined by comparison to a standard curve generated using
recombinant murine IL-2 (PharMingen) using SOFTmaxPro
version 1.1 software.
FACS® Analysis of TCR Downregulation. The stimulation of
the T cell hybridomas was carried out in parallel and under the
same conditions as the antagonism assays mentioned above. To
ensure conjugate formation, cells were centrifuged briefly. Simi-
lar results were obtained with round- or flat-bottom 96-well
plates. After 3 h of stimulation at 378C, cells were washed once in
PBS containing 1% FCS and 0.05% azide, and stained with satu-
rating amounts of PE-conjugated anti-Va2.1 mAb (B20.1) and,
in the case of the double TCR expressing cells, with biotinylated
anti-Vb5 (MR9-4) or anti-Vb10 (B21.5) mAbs. For the anti-
Vb10 mAb, streptavidin-APC (PharMingen) was used as a sec-
ond step labeling reagent. The P1.32Kb cells were excluded by
staining with anti-Kb FITC labeled mAb (AF6-88.6). Dead cells
were excluded by staining with 0.5 mg/ml propidium iodide
(Molecular Probes). Results were analyzed using CellQuest ver-
sion 3.1 software.
Tyrosine Phosphorylation Assays. For antigen presentation, the
cell line P1.32Kb was loaded either with medium alone or with
antigenic peptides, 10 mM SSIEFARL or 1 mM SIINFEKL, in a
24-well plate overnight (7.5 3 105 cells/well in 1 ml 1.5% FCS
IMDM). 107 responding T cell hybridomas were then added to
each well and incubated at 378C for 30 min. Cells were harvested
and cell pellets were lysed for 20 min in 1 ml of 1% Triton X-100,
10 mM Tris-NCl, pH 7.4, and 150 mM NaCl. To prevent deg-
radation, the lysis buffer was supplemented with 10 mM NaF, 1
mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM
orthovanadate, and 100 mM pervanadate (made from a fresh
stock solution of 10 nM orthovanadate and 15 mM H2O2). Cell
lysates were immunoprecipitated with anti-Vb5, anti-Vb10
mAbs, or anti-CD3e, respectively, and resolved by SDS-PAGE as
described previously (51). Proteins were transferred onto nitro-
cellulose and the membrane was blocked with 1% BSA/TBS
0.1% NP-40 (BSA stock solution; Pierce) for 20 min at room
temperature. Blots were probed with 1 mg/ml of the biotinylated
antiphosphotyrosine mAb, 4G10 (Upstate Biotechnology) for 1 h
at room temperature in 1% BSA/TBS 0.1% NP-40. Bound 4G10
antibodies were visualized with streptavidin-HRPO (1:50,000;
Southern Biotechnology Associates) and an enhanced chemilu-
minescence system (Pierce).
Anti-z Blot. After phosphotyrosine detection, HRPO was
inactivated by incubating the nitrocellulose membranes with 3%
H2O2/H2O for 15 min at room temperature. Subsequently non-
specific binding was blocked with 5% milk/PBS 0.1% NP-40
(nonfat dry milk; BioRad) for 20 min at room temperature. Blots
were probed with 100 ng/ml biotinylated anti-z mAb H146-968
for 1 h at room temperature. Bound anti-z antibodies were visu-
alized with goat anti–hamster HRPO (1:50,000; Southern Bio-
technology Associates) and an enhanced chemiluminescence sys-
tem (Pierce).
Results
Antagonism in Va2Vb5 (OT-I) TCR Expressing T Cell
Hybridomas. To investigate the mechanism of TCR an-
tagonism, we took advantage of the T cell hybridoma line,
58CDa/bTCR-a2/b2, which expresses the coreceptor
CD8 but no endogenous TCR (41; see Materials and
Methods). Using retroviral vectors, we transduced the
cDNAs encoding the Va2Vb5 TCR, which is known as
OT-I. This TCR specifically recognizes the ovalbumin
peptide, SIINFEKL, bound to the MHC class I molecule
Kb (9). Two antagonist peptides, E1 and P7, differing by
only one residue from the antigenic peptide, have been de-
scribed for this TCR (32). Optimal activation of the
Va2Vb5 expressing hybridomas, measured by the secre-
tion of IL-2 or IL-3 and TCR internalization, required
high expression of both CD8a and CD8b, (52; and data
not shown).
The agonist peptide was prepulsed onto the APC to en-
sure antigen binding as previously described for conven-
tional antagonism assays (9). Antagonism was observed
with similar characteristics described for T cell clones (Fig.
1). The Va2Vb5 expressing cells responded to the anti-
genic peptide SIINFEKL by secreting IL-2 and IL-3 in an
antigen dose-dependent fashion and the presence of the an-
tagonist peptides, E1 and P7, inhibited IL-2 and IL-3 pro-
duction at suboptimal SIINFEKL concentrations (Fig. 1 A
[IL-3 data not shown]). This inhibition of the response was
specific for the antagonist peptides since a control MHC
Kb-binding peptide, K4, neither inhibited nor potentiated
Figure 1. TCR antagonism in 58CD8a/b T cell hybridomas express-
ing the Va2Vb5 (OT-I) TCR. T cell hybridomas were stimulated with
their antigen, SIINFEKL, and the effect of the antagonist (E1, P7) and
control (K4) peptides on IL-2 response (A) and TCR downregulation (B)
was measured. The arrow highlights the data showing that, in the absence
of SIINFEKL, neither the antagonists E1 and P7, nor the control peptide
K4 induced TCR internalization. The IL-2 response (A) was determined
after 25 h of stimulation, while the TCR downregulation (B) was analyzed
after 3 h. Data are expressed as mean of triplicates in A or of duplicates in
B. This experiment is representative of eight separate experiments.256 TCR Antagonism without a Negative Signal
the IL-2 response elicited by the peptide SIINFEKL alone
(Fig. 1 A).
Functionally triggered TCRs are internalized shortly af-
ter stimulation. Thus, downregulation of TCRs after expo-
sure to the antigenic peptide, SIINFEKL, was used as a
measure for productive TCR engagement (53, 54). As
shown in Fig. 1 B, up to 75% of Va2Vb5 TCRs were
downregulated in a dose-dependent fashion after 3 h of an-
tigen exposure. Neither antagonist peptides alone nor the
control peptide K4 affected TCR expression (Fig. 1 B, see
arrow). However, both antagonist peptides, E1 and P7,
modestly inhibited (by 10%) TCR downregulation in-
duced by the antigen, SIINFEKL. Although the reversal of
TCR internalization correlated with the inhibition of IL-2
secretion (Fig. 1, A and B), the effect on IL-2 secretion was
more pronounced. Surprisingly, the number of internalized
TCRs did not necessarily correlate with the amount of se-
creted IL-2. This was particularly evident when the re-
sponse to 1 nM SIINFEKL was antagonized by 10 mM E1
or P7 (compare A and B in Fig. 1 and in Fig. 5). Under
these conditions, TCR downregulation was not inhibited,
although a significant decrease in IL-2 secretion was ob-
served. These results suggest that in this system there is
no strict correlation between the inhibition of antigen-
induced TCR internalization and the effect on the IL-2 re-
sponse.
Expression of Two TCRs Which Share a Common TCR a
Chain on the Same Cell. To test the hypothesis that antag-
onist ligands induce intracellular, dominant-negative sig-
nals, we generated a T cell hybridoma line expressing two
TCRs, which could be independently activated. This ex-
perimental design was used to determine whether positive
signals derived from an antigen-stimulated TCR could be
blocked by putative inhibitory signals generated by a sec-
ond, antagonized TCR (Fig. 2). One receptor is the
Va2Vb5 TCR, which is specific for the antigenic peptide,
SIINFEKL, and which can be antagonized by the altered
peptides, E1 and P7 (32; Fig. 1). The Va2 chain is also
present in the second receptor but is paired instead with a
Vb10 chain. This second TCR is specific for a Herpes sim-
plex viral peptide, SSIEFARL, also presented by Kb (40).
Since the two receptors differ only in their TCR b
chains, no hybrid receptors of unknown specificities can be
formed and the two receptors can easily be followed with
Vb-specific antibodies. Therefore, all observed effects can
be clearly attributed to the respective receptor.
Both Agonists, SIINFEKL and SSIEFARL, and the Antag-
onists, E1 and P7, Are TCR Specific. First, we determined
whether the two receptors, which have a common TCR a
chain, are specific for their respective antigenic peptides. T
cell hybridomas expressing only one type of TCR, either
Va2Vb5 or Va2Vb10, were analyzed for their IL-2 re-
sponse in stimulation assays. As shown in Fig. 3 A, Va2Vb5
expressing cells responded only to the antigen, SIINFEKL,
while Va2Vb10 expressing cells were stimulated only by
the peptide SSIEFARL (Fig. 3 B). Neither of these TCRs
was stimulated by the antagonist peptides, E1 and P7, or
by the control peptide, K4 (Fig. 3, A and B). Moreover,
TCR internalization completely correlated with the IL-2
responsiveness (data not shown).
A reduced IL-2 response to SSIEFARL compared to
SIINFEKL (Fig. 3) was observed. However, this difference
could not be attributed either to different TCR expression
levels or to differences in the ability of these antigens to
bind Kb. The binding affinities of the peptides to Kb, indi-
rectly measured by their abilities to stabilize Kb expression
on RMA-S cells, were equivalent (data not shown). The
lower IL-2 response, induced by the SSIEFARL peptide,
was likely due to weak interactions of the Va2Vb10 TCR
with this peptide/MHC complex. Nevertheless, the IL-2
production in response to SSIEFARL demonstrated that
the Va2Vb10 TCR was functional.
To determine if the Va2Vb5-specific antagonists, E1
and P7, could antagonize the Va2Vb10 TCR directly,
cells expressing only the Va2Vb10 receptor were stimu-
lated with the cognate antigen, SSIEFARL, in the presence
of the Va2Vb5-specific antagonist peptides, E1 and P7, or
the control peptide, K4. None of the peptides inhibited the
IL-2 response to SSIEFARL (Fig. 4 A) or the downregula-
tion of the Va2Vb10 receptor (Fig. 4 B). These results
showed that the antagonists of the Va2Vb5 TCR did not
cross-react with the Va2Vb10 receptor.
Antagonists of SIINFEKL Act Locally and in Cis. Having
confirmed the specificity of the two TCRs expressed on
separate hybridomas, both receptors were expressed on the
same cell. Two-color FACS® analysis with anti-Vb anti-
bodies was used to calculate that Va2Vb5 and Va2Vb10
comprised 60 and 40% of the surface TCRs, respectively
(data not shown). Stimulation of the double TCR express-
ing cells with either the Va2Vb5- or Va2Vb10-specific
antigen resulted in a low but reproducible IL-2 response
(Fig. 5, A and C). Thus, both TCRs were functional when
Figure 2. Coexpression of two peptide-specific TCRs on the surface
of the same cell. One receptor is the Va2Vb5 TCR which is specific for
the ovalbumin peptide, SIINFEKL, presented by Kb. This TCR can be
antagonized by the altered peptide ligands, E1 or P7. The K4 peptide
represents a control for peptide specificity since it has the similar binding
affinity to Kb but is not recognized by the Va2Vb5 TCR. The second
receptor is the Va2Vb10 TCR and is specific for the Herpes simplex vi-
ral peptide, SSIEFARL, bound to Kb. Both receptors were coexpressed
on the T cell hybridoma line 58CD8a/b.257 Stotz et al.
expressed at the surface of the same cell. An antagonist as-
say was performed by stimulating the dual expressing hy-
bridoma cells with the Va2Vb5 antigen SIINFEKL, in the
presence of the Va2Vb5-specific antagonists E1 or P7.
Both antagonist peptides, but not the control peptide K4,
inhibited IL-2 expression in the dual TCR expressing cells
(Fig. 5 A). Additionally, the antigen-induced TCR inter-
nalization of Va2Vb5 receptor was slightly inhibited in the
presence of the antagonists E1 and P7 similar to what was
observed previously (Fig. 5 B and Fig. 1 B).
To test the hypothesis that antagonist ligands deliver a
negative, trans-acting signal, the double receptor expressing
cells were stimulated with the Va2Vb10-specific antigen,
SSIEFARL, in the presence of the Va2Vb5-specific antag-
onist peptides E1 or P7. The IL-2 response to SSIEFARL,
mediated by the Va2Vb10 TCR was unaffected in the
presence of the Va2Vb5-specific antagonist peptides E1 or
P7 (Fig. 5 C). Furthermore, the Va2Vb5-specific antago-
nists did not reverse the downregulation of the Va2Vb10
TCR (Fig. 5 D).
The results clearly show that antagonizing one TCR did
not inhibit the stimulation through a second, independent
TCR. Apparently, these antagonist ligands do not induce a
dominant-negative signal that acts in trans.
Antigen-engaged TCRs Function Independently in Their Proxi-
mal Signaling Pathways. Since the antagonized Va2Vb5
TCR did not interfere with the response of the stimulated
Va2Vb10 TCR, we investigated the functional indepen-
dence of the two receptors. To find out if both receptors
function independently, both TCRs were monitored for
antigen-induced TCR internalization. The stimulation
with the Va2Vb5-specific antigen, SIINFEKL, resulted in
downregulation of the Va2Vb5 TCR but not of the
Va2Vb10 TCR (Fig. 6 A). Similarly, in response to the
Va2Vb10-specific antigen, SSIEFARL, the Va2Vb10 re-
ceptor was downregulated, while no internalization of the
Va2Vb5 receptor was detectable (Fig. 6 B). Similar results
were obtained when various cell populations expressing
different ratios of the two TCRs were used (not shown),
supporting the observations of Valitutti et al. examining T
cell clones with disparate expression of the two TCRs (53).
To address whether two different TCRs expressed on
the surface of the same cell also behave independently in
regard to biochemical signaling, T cell hybridomas express-
ing the two TCRs were incubated with unpulsed APCs or
APCs pulsed with either the Va2Vb10-specific antigen,
SSIEFARL, or the Va2Vb5-specific antigen, SIINFEKL.
From cell lysates, both TCRs were either immunoprecipi-
tated with an anti-CD3e mAb, or independently retrieved
using anti-Vb5– or anti-Vb10–specific mAbs. Immunopre-
cipitates were resolved by SDS-PAGE and blotted for the
presence of phosphorylated tyrosine residues. Only low back-
Figure 3. The two TCRs are distinctly specific for their cognate anti-
genic peptides. The TCRs, Va2Vb5 (A) and Va2Vb10 (B), were ex-
pressed separately on the cell line 58CD8a/b and tested for their respon-
siveness to various peptide analogues in stimulation assays by measuring
the IL-2 production. After 25 h of stimulation, supernatants were har-
vested and analyzed for IL-2. This experiment is representative of two in-
dependent experiments.
Figure 4. The Va2Vb5-specific antagonist peptides E1 and P7 do not
antagonize the response of the Va2Vb10 TCR to the Herpes simplex vi-
ral peptide, SSIEFARL. Va2Vb10 58CD8a/b hybridomas were stimu-
lated with various concentrations of SSIEFARL in the presence of the
Va2Vb5-specific antagonists, E1 and P7, or control peptide, K4. The IL-2
response (A) and antigen-induced TCR internalization (B) were mea-
sured in the same experiment and are representative of two independent
experiments.258 TCR Antagonism without a Negative Signal
ground phosphorylation of TCR-associated proteins was
observed in T cell hybridomas exposed to unpulsed APCs
(Fig. 6 C, lanes 1–3). In contrast, incubation with APCs
pulsed with 10 mM SSIEFARL induced a strong phosphor-
ylation of various proteins which coimmunoprecipitated
with the TCR. In anti-CD3e and anti-Vb10 immunopre-
cipitates, tyrosine-phosphorylated isoforms of z (p21 and
p23), CD3e, ZAP-70, and a 36-kD phosphoprotein, most
probably LAT, were observed (Fig. 6 C, lanes 4 and 6). To
test for the phosphorylation of unstimulated bystander
TCRs, the Va2Vb5 complex was immunoprecipitated
from lysates of cells which had been stimulated with the
Va2Vb10-specific antigen, SSIEFARL. There was no de-
tectable induction of phosphorylation of any protein species
precipitated with the Va2Vb5 TCR complex (Fig. 6 C,
lane 5). Similar results were obtained with the reverse ex-
periment. In stimulations with 1 mM of the Va2Vb5-spe-
cific antigen, SIINFEKL, only anti-CD3e and anti-Vb5 im-
munoprecipitates showed the induction of phospho-z (p21
and p23), CD3e, ZAP-70, and the 36-kD phosphoprotein
(Fig. 6 C, lanes 7 and 8). Immunoprecipitation of the by-
stander TCR, Va2Vb10, did not coprecipitate any of the
same phosphorylated proteins (Fig. 6 C, lane 9). As the sub-
sequent decoration of the same blot with anti-z showed,
both anti-Vb–specific antibodies immunoprecipitated simi-
lar amounts of z. The anti-CD3e mAb was sixfold more ef-
ficient in coprecipitating z than both Vb-specific mAb (Fig.
6 C, bottom).
To determine the sensitivity of detection, the eluate of
cells stimulated with 10 mM antigenic peptide was serially
diluted (twofold) to determine the detection limits of the
phosphoproteins (data not shown). These experiments
showed that as little as 5% of the phosphorylated z (shown
in Fig. 6 C, lane 4) could be detected. Thus, the biochem-
ical activation of bystander TCRs is very limited, if it oc-
curs at all. The combined results demonstrate that the two
TCRs expressed on the same cell are biochemically and
functionally independent.
Figure 5. Engagement of one TCR with antagonist peptides does not
inhibit the activation through a second independent TCR. Analyzing
cells simultaneously expressing both Va2Vb5 and Va2Vb10 TCRs on
the cell surface, the Va2Vb5-specific antagonist peptides, E1 and P7, in-
hibited the IL-2 production (A) and the TCR downregulation (B) in-
duced by the Va2Vb5-specific antigenic peptide, SIINFEKL. However,
the Va2Vb5-specific antagonists, E1 and P7, did not inhibit the IL-2 re-
sponse (C), nor the TCR downregulation (D) induced by the Va2Vb10-
specific antigen, SSIEFARL. The IL-2 response (A and C) and TCR
downregulation (B and D) were assayed in the same experiment. The
data are representative of six separate experiments.
Figure 6. Antigen-engaged TCRs behave independently with regard
to antigen-induced TCR internalization and biochemical signaling. The
double TCR expressing hybridomas were stimulated with the Va2Vb5-
specific antigen, SIINFEKL (A), and the Va2Vb10-specific antigen,
SSIEFARL (B). TCR downregulation of both receptors was analyzed.
The data are representative of three independent assays. To study the in-
duction of TCR-associated phosphoproteins (C), P1.32Kb APC were
pulsed overnight with medium alone (no stimulation) or with the anti-
genic peptides, 10 mM SSIEFARL or 1 mM SIINFEKL. 107 double
TCR expressing cells, Va2Vb5/Vb10 58CD8a/b, were stimulated for
45 min at 378C. Proteins in cell lysates were immunoprecipitated with
anti-Vb5 mAb (MR9-4), anti-Vb10 mAb (B21.6), or anti-CD3e mAb
(2C11), respectively, separated on a 12% polyacrylamide gel, and trans-
ferred to nitrocellulose. The blot was probed with the anti-phosphoty-
rosine mAb, 4G10, and then with the anti-z mAb, H146-968. The ar-
rows on the left identify the major tyrosine-phosphorylated species.259 Stotz et al.
The Antagonists E1 and P7 Do Not Alter the Kinetics of
TCR Internalization. Since antagonist ligands do not in-
duce a dominant-negative signal, antagonist peptides may
outcompete agonist peptides for interaction with the TCR.
As shown in Fig. 1 B antagonist ligands only slightly inhib-
ited the antigen-induced TCR downregulation. In fact, the
extent of TCR internalization in the presence of antagonist
peptides did not reflect the profound inhibition of IL-2 se-
cretion observed (Fig. 1). To assess whether antagonist
peptides perturb T cell stimulation by affecting the kinetics
of agonist-induced TCR downregulation, we monitored
TCR internalization over time (Fig. 7). Antagonist pep-
tides affected the extent but not the kinetics of antigen-
induced TCR internalization. The full extent of TCR
downregulation was reached after 2–3 h of sustained anti-
gen exposure.
Susceptibility to Antagonism Parallels the Time of Commit-
ment to T Cell Activation. To better understand the events
that led to antagonism, the time period when cells are sen-
sitive to antagonist ligands was determined. T cell hybrido-
mas, expressing the single TCR, Va2Vb5, were stimulated
with the antigenic peptide, SIINFEKL, and antagonist pep-
tides were added at various time points thereafter. The ad-
dition of antagonist peptides could fully inhibit the IL-2 re-
sponse up to 12 h after addition of the antigen, SIINFEKL
(Fig. 8). This effect was peptide-specific as the control pep-
tide, K4, did not abrogate the IL-2 response.
To determine whether the time period during which T
cells are susceptible to antagonist ligands overlapped with
the time period required for T cell commitment, the Kb-
specific antibody, Y3, was used to specifically block the in-
teraction of the Va2Vb5 TCR with the SIINFEKL/Kb
complex. The time required for sustained TCR engage-
ment, determined using the blocking antibody, Y3, corre-
lated exactly with the period of susceptibility to antagonist
peptides (Fig. 8). The cells were irreversibly committed to
IL-2 secretion only after 12 h of continuous exposure to
the antigen ligand, in the absence of antagonist peptides or
blocking mAbs.
Thus, antagonist ligands were able to inhibit cellular re-
sponses long after the responding T cell had interacted with
its cognate antigen and achieved a reduced steady-state
level of TCR expression. The T cell was fully sensitive to
the inhibitory effects of antagonist ligands until it did not
require further engagement with the antigen/MHC com-
plex and was irreversibly committed to respond.
Discussion
T cell antagonism has been implicated as a potentially
important mechanism in T cell activation, thymic develop-
ment, escape from an antiviral immune response, and au-
toimmunity. Although the actual mechanism by which an-
tagonists exert their effect is still unresolved, various models
seek to explain the paradox of how the recognition of al-
tered peptide/MHC ligands leads to altered T cell re-
sponses. Quantitative models postulate that antagonist
ligands inhibit T cell responses by competing for TCR en-
gagement with the antigenic peptide. Due to their lower
affinity and faster off-rate kinetics of TCR binding (23–
25), antagonists are ineffective in initiating downstream sig-
naling pathways but nevertheless reduce the rate of success-
ful TCR engagements by the antigenic peptide (7, 12, 17,
Figure 7. The kinetics of antigen-induced TCR internalization are un-
altered in the presence of antagonist ligands. P1.32Kb APCs were pulsed
for 4 h at 378C with 100 pM antigenic peptide SIINFEKL. Unbound
peptides were removed and the cells were incubated for 1 h with 10 mM
antagonist peptides E1 or P7, or 10 mM control peptide K4, or medium
alone (no peptide added). The responders, hybridomas expressing the
Va2Vb5 TCR, were added at various time points. T cell–APC conju-
gates were formed by centrifugation and all samples were harvested and
stained at the same time. TCR surface expression was detected by PE-
labeled anti-Va2 (B20.1) and expressed as percentage of mean channel
fluorescence of the unstimulated cells. The data are representative of four
experiments.
Figure 8. Susceptibility to antagonist ligands corresponds to the time of
commitment. Va2Vb5 58CD8a/b cells were stimulated with P1.32Kb
cells which had been prepulsed with 100 pM SIINFEKL peptide for 4 h
at 378C. At various time points after the initiation of the stimulation, an-
tagonist peptides E1 or P7, control peptide K4, anti-Kb blocking antibody
Y3, or medium alone were added, and the cells were resuspended. After
25 h of culture, the supernatant was harvested and assayed for IL-2 pro-
duction. For more convenience, the kinetic analysis was carried out in
two parts separated by 12 h. The mean of secreted IL-2 obtained in the
samples where no antagonist peptides were added was set as 100%. The
data are representative of four independent experiments.260 TCR Antagonism without a Negative Signal
19, 54, 55). In contrast, qualitative models characterize an-
tagonists as ligands capable of delivering differential (8, 9,
16, 21, 26–28) or even negative signals to the T cell which
subsequently inhibit T cell activation (13, 14, 31).
By coexpressing two TCRs of independent specificity
on the same cell (Fig. 2), we were able to directly address
the issue of whether a dominant-negative signal is induced
by antagonist ligands. If antagonist peptides generate an in-
tracellular dominant-negative signal, downstream from the
site of TCR engagement, then antagonist ligands would be
expected to inhibit the ability of a second, independent
TCR to induce a cellular response. Our experimental sys-
tem clearly shows that in cells expressing two TCRs, acti-
vation through one TCR is not inhibitable by engaging a
second TCR with antagonist ligand (Fig. 5 C). These re-
sults are supported by the following observations, that (a)
the antigenic peptide for the Va2Vb10 TCR, SSIEFARL,
is a weak agonist (whose weak stimulatory capacity is defi-
nitely not due to weak MHC binding affinity as deter-
mined by RMA-S stabilization, data not shown). There-
fore, a weak stimulation through Va2Vb10 should have
been easily inhibitable by a putative negative signal through
the Va2Vb5 TCR; (b) the ratio of the two TCRs ex-
pressed on the same cell favored the signals through the an-
tagonized TCR since Va2Vb5, recognizing the antagonist,
represented 60% of the TCR on the cell surface; and (c) all
peptides were presented on the same APCs (agonist was
loaded first to ensure its binding to Kb), therefore even a
putative negative signal with only short-range efficacy
should have been detected.
The fact that we observed no functional interference be-
tween different TCRs expressed on the same cell and no
bystander TCR downregulation upon antigenic stimula-
tion (Fig. 6, A and B) suggests that these two TCRs func-
tion independently, supporting the findings of Valitutti et al.
on T cell clones (53). This is further supported by the bio-
chemical data in hybridomas expressing two TCRs. Phos-
phorylated z and recruited phospho-ZAP-70 were only
coprecipitated from TCRs engaged with their respective
antigen (Fig. 6 C). These experiments argue that the phos-
phorylation of engaged TCRs does not spread to unen-
gaged TCRs. It remains possible that individual cells ex-
pressing two different TCRs are intrinsically able to engage
only one type of TCR. However, the simultaneous expo-
sure of the cells to both antigenic peptides, the Va2Vb5-
specific SIINFEKL and the Va2Vb10-specific SSIEFARL,
presented on the same APC, induced concomitant inter-
nalization of both TCRs, indicating that both TCRs are
functional on the same cell (data not shown).
Taken together, our data indicate that these antagonist
ligands do not act by generating dominant-negative signals
which inhibit the response of the entire cell. Therefore, we
favor a quantitative model to explain TCR antagonism.
Antagonist ligands have faster off-rate kinetics for TCR en-
gagement than agonist ligands (23–25). Thus, antagonist
ligands engage the TCR for a longer time than null pep-
tides, but not long enough to induce the full signaling
cascade for activation, as first suggested by the kinetic
proofreading model of McKeithan (18). Although this inef-
fective engagement does not lead to full activation, it does
generate differential biochemical signals reflected by the
differential phosphorylation patterns of z (p21 . p23; refer-
ence 28). However, as the data from our experimental sys-
tem have shown, these differential signals did not represent an
intracellular, negative signal per se. As a consequence of inef-
fective TCR engagement, antagonist ligands prevent agonist
ligands from serially engaging and triggering enough TCRs
to reach the critical threshold for activation (53). This compe-
tition for TCR engagement can be observed in the inhibi-
tion of TCR downregulation in the presence of antagonist
ligands (19; Fig. 1 B and Fig. 5 B). Furthermore, the quanti-
tative mechanism of antagonist action also explains the ob-
servation that T cell responses are less efficiently inhibited
when antagonists and agonist peptides are presented on dif-
ferent APCs (9; data not shown). Conditions which reduce
the direct competition between agonist and antagonist
ligands reduce the efficiency of TCR antagonism. Antago-
nist ligands may also influence the reorganization of TCRs
which may be required for full activation (55–57).
Although our data indicate that these antagonist ligands
do not induce an intracellular negative signal, downstream
from TCR engagement, there are potentially some limita-
tions to the interpretation of our results. It is possible that
for some unknown reason, the Va2Vb10 receptor could
not be inhibited. In this regard, the Va2Vb10 TCR in-
duced a strong degree of tyrosine phosphorylation but rela-
tively little IL-2 secretion. This is somewhat surprising with
regard to previously published data where a strong correla-
tion between the degree of tyrosine phosphorylation and
the extent of the functional responses was observed (26, 27,
58, 59). Whether this indicates that the Va2Vb10 receptor
is intrinsically incapable of responding to a negative signal is
difficult to know. A reciprocal study using antagonists for
the Va2Vb10 TCR and agonist ligands for the Va2Vb5
receptor would have been informative, but antagonists for
SSIEFARL (ligand for the Va2Vb10 receptor) have not
been identified. It is also possible that antagonist peptides
deliver negative signals which only inhibit other identical
TCRs. If these putative negative signals are cis-limited,
then we would not have been able to detect them using a
second, independent receptor.
It is also theoretically possible that antagonist ligands
generate dysfunctional TCRs, e.g., by inducing a confor-
mation that disables the receptor from further activation.
However, preexposure to antagonist peptides for 4 h alone
did not render the Va2Vb5 expressing hybridomas cells
unresponsive to further antigenic stimulation (data not
shown), which is in accord with the findings of Preckel et al.
for CD81 T cell clones (19). Moreover, since the signaling
capacity of a second independent TCR was unaffected, it is
also unlikely that antagonist peptides alter T cell responses
by consuming limited amounts of signaling intermediates.
There are two reports of antagonists that can inhibit T
cell responses when present at substoichiometric ratios rela-
tive to the antigenic peptide (10, 11). These types of antag-
onist peptides may not function by competition and con-261 Stotz et al.
ceivably could deliver a negative signal to the responding T
cell. Thus, there may be different classes of antagonist pep-
tides that act through different mechanisms. One class that
was studied here must be present in molar excess to exert
an inhibitory effect and uses a competitive mechanism to
inhibit T cell responses. Other classes of TCR antagonists,
which are effective at substoichiometric ratios, may work
by a dominant-negative mechanism.
Our data also show that neither the extent of inhibition
(Fig. 1 B) nor the kinetics (Fig. 7) of TCR internalization
fully accounted for the inhibition of IL-2 response in our
experimental system. In fact, these data demonstrate that
antagonist peptides can fully exert their inhibitory effect
well after the initial phase of TCR downregulation, at a
stage where there is no further net loss of surface TCRs
(Fig. 8). Furthermore, the blocking studies with the anti-Kb
antibody, Y3, demonstrated that the time window of sus-
ceptibility to antagonism correlated exactly with the time
of commitment.
Previous studies have already pointed out the impor-
tance of a sustained signal for T cell commitment (60–62).
Depending upon the amount of available antigen, the type
of APC, the number of adhesion and costimulatory mole-
cules present on the APC, and the state of differentiation of
the responding cell, the length of time required for T cell
commitment varied (63). For the Va2Vb5 expressing T
cell hybridoma, 12 h of continuous engagement with the
agonist ligand was required for a commitment to IL-2 se-
cretion. On the other hand, internalization of TCRs
reached a steady-state after 2–3 h of antigen exposure (Fig.
7). After this point there may be continued TCR down-
regulation, but there is no further net loss of TCR from the
cell surface. These data suggest that antagonist peptides
competitively inhibit agonist ligands from productively en-
gaging TCR during the entire commitment period. There-
fore, it is conceivable that small changes in the rate of TCR
engagement, integrated over time, may have a significant
impact on the final outcome of T cell activation.
Nevertheless, antagonist as well as partial agonist ligands
induce biochemical signals, which are different from the
signaling events generated by antigenic ligand used over a
broad range of concentrations (28). Altered peptide ligands
have been shown to induce altered phosphorylation of the
z chain without stable phosphorylation of CD3e and ZAP-
70 (26–28). That partial agonists induce differential bio-
chemical signaling events as well as a long lived anergy in
CD41 T cell clones (20, 26, 64) has led some investigators
to postulate that altered peptide ligands generate quali-
tatively different signals (26). In principle, the anergic state
could result from the consumption of limiting signaling in-
termediates or from an imbalanced expression of transcrip-
tion factors (65). Since T cell hybridomas, which are not
IL-2 dependent for their proliferation, were used in these
studies, we could not directly address this issue. Neverthe-
less, our experiments suggest that the inhibition of IL-2
production, a feature which characterizes most anergic T
cells, is not mediated by a negative signal.
In summary, the data are consistent with the idea that
the antagonist ligands studied here do not deliver negative
signals, but rather compete with antigenic ligands for TCR
engagement. This competition can effectively inhibit T cell
responses by reducing the rate of TCR engagement
throughout the entire commitment period.
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